RAPP · Rapport Therapeutics, Inc.

Current Thesis

The binary that defined this name last month has come and gone. At the 2026 AAN annual meeting on 2026-04-21, Rapport presented the RAP-219 focal-onset-seizure (FOS) Phase 2a follow-up data, and the numbers held up: a 90% median clinical-seizure reduction in weeks 9-12 and 59% in weeks 13-16, with an 80%/68% median reduction in long episodes across the same windows, plus a newly disclosed ~22-day half-life and a clean tolerability profile. The data validated the durability question and the stock fell roughly 9% on the print. That is the whole story right now: a confirmed thesis met by profit-taking after a 5× run, and a tape that has not made a new high since the April peak. With the FOS efficacy question answered and Phase 3 a multi-year readout, the name has entered a ~5-month data gap. The next event that can actually move the stock is bipolar-mania Phase 2 topline, now pulled forward to Q4 2026. The narrative is intact and de-risked, but the accelerating leg an investor would chase has already been ridden; what is left until autumn is consolidation and burn. This is a validated story trading sideways, not a momentum entry.

Bull Case

• Durability confirmed, not just headline efficacy (AAN, 2026-04-21): 90% median clinical-seizure reduction weeks 9-12 and 59% weeks 13-16, after the Dec-2025 topline already showed ~77.8% median reduction. The follow-up period was the open question; it answered well.
• 22-day half-life (disclosed 2026-04-21, revised up from a ~14-day estimate): explains the carryover seizure control after dosing and directly underwrites the long-acting-injectable program a differentiated dosing profile versus daily ASMs.
• Bipolar topline accelerated to Q4 2026 (Q1 update, 2026-05-07), from prior H1 2027. Enrollment was increased and the statistical plan modified to potentially support confirmatory evidence pulling a second binary shot-on-goal forward by ~two quarters.
• Funded through the catalysts: $476.8M cash at Q1 2026, runway guided into H2 2029. Phase 3 FOS enrollment is covered without a forced raise.
• Competitive position reinforced: a rival epilepsy readout disappointed around the same AAN window, which sell-side framed as strengthening RAP-219's γ8-selective differentiation versus broad AMPAR antagonism (Fycompa-style tox).
• Sell-side still constructive: consensus Strong Buy across 6-8 desks, average PT roughly $48-57 (range $28-$80) against a ~$36 quote implied upside if the next catalysts land.

Bear Case

• Sell-the-news already triggered: strong data, -9% reaction (2026-04-21). When good news cannot lift a 5× stock, the marginal buyer is exhausted and the easy narrative-acceleration money is gone.
• Five-month data void: nothing data-moving prints between the April follow-up and bipolar topline in Q4 2026. Phase 3 FOS initiation (guided Q2 2026) is an operational milestone, not a catalyst markets rarely pay for a trial-start PR.
• Single-molecule platform, correlation ≈1: one tox/hepatic/CV SAE in any indication impairs FOS, bipolar mania, PGTCS and the LAI simultaneously. There is no internal diversification to cushion a safety surprise, and the 22-day half-life means slow washout if one appears.
• Burn is accelerating: Q1 R&D $32.7M and G&A $11.5M (~$44M/quarter) versus ~$27M a year earlier; net loss $19.9M. Cash is ample but the quarterly drain widens as Phase 3 ramps.
• No momentum structure to lean on: lower highs since the April peak, drifting from the low-$40s toward the mid-$30s. There is no accelerating trend and no fresh catalyst to re-ignite one before Q4.
• Open-label, small-n proof-of-concept: the FOS data comes from 30 RNS-implanted patients in an open-label study; Phase 3 is the first controlled, blinded test, and the read-through is years out.

Setup & Price Structure

• Last: $36.10 (2026-06-05 close, -3.71% on the day; after-hours ~$35.38)
• 52-wk range: $10.51 $42.27. Current price is ~15% below the April high and ~3.4× off the low well off the floor, not at it.
• Market cap: ~$1.73B; ~47.2M weighted-average shares.
• Structure: the $42.27 high was set into the AAN print; the stock has carved lower highs since, settling into a low-to-mid-$30s consolidation. This is a post-event base, not a breakout. The relevant near-term shelf sits around $32-34, near where the rising 20-EMA has been tracking.
• Read: not stretched above its moving averages, not at peak retail mania but also offering no accelerating leg. A fresh momentum entry here pays for a story that is already validated and now waiting. The cleaner setup is a breakout back through the post-AAN range on volume, or a base built into the Q4 bipolar catalyst window. Until one of those forms, the better stance is to stand aside.

Catalyst Calendar (next 30 days)

• ~2026-06-30 (est.) Phase 3 FOS program initiation, guided "Q2 2026." Operational milestone (first-patient-in / program start), low expected price impact; a slip past Q2 would be a negative tell on execution.
• No data binary inside 30 days. The April AAN follow-up was the last data event; the next is months out.
• ~early August 2026 (est.) Q2 2026 financials and business update; earnings blackout applies in that window.
• Q4 2026 Bipolar-mania Phase 2 topline (accelerated from H1 2027). This is the next true binary and the event worth building a base into.
• H1 2027 PGTCS Phase 3 initiation; LAI Phase 1 PK data expected 2027.

What Would Change Our Mind

• Re-accelerate to constructive: a volume breakout back above the post-AAN range (reclaiming the upper-$30s / prior high) ahead of Q4, signalling the data gap is being bought rather than sold; or a positive Phase 3 design/alignment disclosure that re-rates the registrational path.
• Break the thesis: any 8-K disclosing a RAP-219 clinical hold or new SAE given platform correlation ≈1, that is not an FOS problem, it is a whole-pipeline problem. A weekly close below ~$32 would forfeit the post-AAN base and signal the narrative is bleeding out into the void. A Phase 3 FOS initiation that slips past Q2 2026 would undercut the execution story.
• The trap to avoid: treating the April momentum as still live. The 5× move discounted the FOS thesis; chasing here on the assumption the trend resumes with no catalyst until Q4 is buying a data gap at a premium multiple.

Correlation Notes

• Internal correlation ≈1: every program rides one molecule (RAP-219). FOS, bipolar mania, PGTCS and the LAI line are not independent bets; a single safety event collapses all of them together. Size accordingly this is one binary wearing four labels.
• Sector beta: small-cap clinical biotech moves with XBI risk appetite and rate expectations independent of the pipeline; a -15-20% XBI drawdown drags RAPP regardless of RAP-219 news.
• Theme: precision-neuroscience / targeted-CNS small-caps. Read-through runs both ways a competing AMPAR or precision-CNS readout (positive or negative) reprices the differentiation premium, as the rival epilepsy disappointment around the AAN window already showed.
• Takeout optionality: γ8-selectivity, a clean tox profile and a ~$1.7B cap keep RAPP on the mid-cycle neuro-M&A screen, but acquirers historically wait for controlled Phase 3 signal that optionality is a 2027+ consideration, not a near-term driver.